Brief: Primex Pharmaceuticals Acquires Rights To Ozalin From Advicenne
13/09/2018 12:46
Sept 13 (Reuters) - PRIMEX PHARMACEUTICALS:
* ACQUIRES THE RIGHTS TO OZALIN – THE FIRST ORAL PAEDIATRIC
SEDATIVE LICENSED IN THE EU
Source text for Eikon: ID:nBw9DpL0pa
Further company coverage: ADVIC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Advicenne SA
See all newsBrief: Advicenne Secures Cash Runway To Q2 2027 Through Bond Financing Of Amount Of Up To €3.8 Mln
Corrected: BRIEF-Advicenne FY Net Income EUR -9.532 Million (March 26)
France's Advicenne 2025 sales rise, net loss widens
Brief: Advicenne FY Net Income EUR -9.532 Million
Brief: Advicenne SA -Cash Position Of EUR 2.0 Million With Unchanged Financial Visibility In Q1 2025